Although the approved HH pathway inhibitors (SMO inhibitors) have shown significant antineoplastic activity in a variety of tumors, especially BCC, the diseases relapse and progress within several months due to acquired resistance. The gene discussed is SMO; the disease is skin basal cell carcinoma.